Eurazeo e-news | March 2024

Eurazeo, 16.04.2024


  Eurazeo completed the sale of DORC to Carl Zeiss Meditec AG.
  Our Mid-large buyout portfolio company Questel achieved a new milestone for AI-elevated intellectual property solutions with the strategic acquisition of Qatent.
  Moonfare and Eurazeo’s partnership bears fruit with the launch of Eurazeo Private Value Europe 3 leveraging Moonfare’s technology.
  The specialist in immune system interpretation Surge announces the closing of a €7.5M fund-raising to transform precision medicine.
  Our portfolio company PPRO announced an €85M funding to fuel the growth of its global network of local payment methods.
  Kurma Partners announced the acquisition of its portfolio company Amolyt Pharma by Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease.


  With Saudi Arabia’s flagship Tech conference LEAP 2024 taking place in Riyadh, Matthieu Baret, Mathieu Teisseire, Adrien Pinelli and Othmane Khales were on hand to strengthen Eurazeo’s bond with its Saudi and Middle Eastern partners and deepen Eurazeo’s connection with the local VC ecosystem.
  Eurazeo was in Deauville for Time To Change by Option Finance with insightful panels for our speakers: Sophie Flak, Guillaume Branco, Laurent Chatelin, Pierre Devillard and Sylvain Makaya.
  Our Infrastructure team was in Berlin for the Infrastructure Investor Global Summit, with Laurent Chatelin, Partner – Infrastructure, on an insightful panel dedicated to ‘Addressing climate change and embracing mitigation and adaptation.’.
  We were thrilled to be awarded the CDP A-list at ChangeNOW where we have also been selected from over a hundred participants to showcase our new buyout impact fund.
  Our teams were in Geneva for the Invest Europe Investors’ Forum with Sophie Flak on a panel dedicated to Impact Investing.

Upcoming events...


The protection of your personal data is particularly important for Eurazeo. To find out more about how Eurazeo processes such personal data and what are your rights, see our personal data protection policy. If you no longer wish to receive our emails, click here.